D
Nkarta, Inc. NKTX
$1.95 -$0.06-2.99% NASDAQ
Recommendation
Prev Close
$2.01
Volume
659,821
Avg Vol (90D)
1,411,645
Market Cap
$142.62M
Dividend & Yield
--
52-Week Range
$1.31 - $8.33
P/E (TTM)
--
EPS (TTM)
-$1.66
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Nkarta, Inc. (NASDAQ:NKTX) Receives Average Recommendation of "Buy" from Analysts
4/28/2025 - Ticker Report
Renaissance Technologies LLC Has $1.89 Million Position in Nkarta, Inc. (NASDAQ:NKTX)
4/28/2025 - MarketBeat
Short Interest in Nkarta, Inc. (NASDAQ:NKTX) Declines By 16.5%
4/23/2025 - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Short Interest Down 16.5% in March
4/23/2025 - Ticker Report
Nkarta, Inc. (NASDAQ:NKTX) Receives Average Rating of "Buy" from Brokerages
4/22/2025 - MarketBeat
JPMorgan Chase & Co. Raises Stock Position in Nkarta, Inc. (NASDAQ:NKTX)
4/20/2025 - MarketBeat
Wasatch Advisors LP Boosts Holdings in Nkarta, Inc. (NASDAQ:NKTX)
4/19/2025 - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Shares Purchased by Affinity Asset Advisors LLC
4/17/2025 - MarketBeat
Affinity Asset Advisors LLC Increases Holdings in Nkarta, Inc. (NASDAQ:NKTX)
4/15/2025 - Ticker Report
Nkarta (NKTX) Upgraded to Buy: Here's Why
4/14/2025 - Zacks Investment Research
Nkarta's (NKTX) Buy Rating Reiterated at Needham & Company LLC
4/11/2025 - MarketBeat
Biotech companies shed hundreds of Bay Area jobs in fresh layoffs
4/1/2025 - SiliconValley.com
Biotech companies shed hundreds of Bay Area jobs in fresh layoffs
4/1/2025 - The Mercury News: Business and Tech
Nkarta to Participate in an April Investor Conference
4/1/2025 - GuruFocus
Nkarta to Participate in an April Investor Conference
4/1/2025 - Globe Newswire
Nkarta: Grinding Lower, Trying To Find Support
3/31/2025 - SeekingAlpha
Nkarta: Grinding Lower, Trying To Find Support
3/31/2025 - Seeking Alpha - Long Ideas
Nkarta: Betting On The Turnaround
3/31/2025 - SeekingAlpha
Nkarta: Betting On The Turnaround
3/31/2025 - Seeking Alpha - Long Ideas
Leerink Partnrs Has Strong Forecast for Nkarta Q1 Earnings
3/31/2025 - MarketBeat
What is HC Wainwright's Forecast for Nkarta Q1 Earnings?
3/31/2025 - MarketBeat
William Blair Estimates Nkarta's Q1 Earnings (NASDAQ:NKTX)
3/31/2025 - MarketBeat
HC Wainwright Comments on Nkarta's Q4 Earnings (NASDAQ:NKTX)
3/29/2025 - MarketBeat
Nkarta (NASDAQ:NKTX) Releases Earnings Results, Beats Expectations By $0.06 EPS
3/28/2025 - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Buy" by Brokerages
3/28/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$119.04M
EBIT (TTM)
-$128.19M
Net Income (TTM)
-$108.79M
Balance Sheet
Total Assets (Q)
$501.20M
Total Debt (Q)
$80.27M
Total Liabilities (Q)
$93.23M
Book Value Per Share (Q)
$5.78
Cash Flow
Cash from Operations (TTM)
-$99.70M
Cash from Investing (TTM)
-$129.56M
Cash from Financing (TTM)
$226.08M
Net Change in Cash (TTM)
-$3.17M
Filings
Filing Date
Wednesday, March 26, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
1.17
7-Day Total Return
7.73%
30-Day Total Return
20.37%
60-Day Total Return
-16.67%
90-Day Total Return
-15.58%
Year to Date Total Return
-22.00%
1-Year Total Return
-71.82%
2-Year Total Return
-62.28%
3-Year Total Return
-89.43%
5-Year Total Return
--
52-week Low
Mar 26, 2025 - $1.31
52-week High
May 03, 2024 - $8.33
Valuation
Market Cap
$142.62M - Micro Cap
Enterprise Value
-$44.46M
Price/Sales (TTM)
--
Price/Book (Q)
0.35
Dividends and Shares
Shares Outstanding
73.60M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.nkartatx.com
Phone Number
925 407 1049
Address
1150 Veterans Boulevard
South San Francisco, CA 94080
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company’s lead product... more
NASDAQ 04/29/2025 4:00PM Eastern Quotes delayed